Mei Mei Hu, JD
Co-Founder and Chief Executive Officer
Ms. Hu is member of the executive committee of United Biomedical Inc., and a member of its Board of Directors. Ms. Hu was formerly a consultant at McKinsey & Co. in the New York office where she advised leading pharmaceutical and commodities companies on strategic, operational and organizational issues. While there, she was a firm expert on managing through economic cycles and developed a next generation risk assessment model for companies. Prior to that, Ms. Hu was in the Securities group at Cravath, Swaine and Moore. Ms. Hu is also co-founder and partner at Jack Green Group, an investment and advisory firm. She received her B.A. degree in Economics from University of Pennsylvania and her JD from Harvard Law School.
Dr. Ajay Verma, MD, PhD
Chief Medical Officer
Ajay Verma is a neurologist who is devoted to the advancement of neurotherapeutics and neurodiagnostics. He studied zoology at the University of Maryland and received his MD and his PhD in neurotoxicology from The Johns Hopkins University, training with Dr. Solomon Snyder. His neurology residency training was in the US Army at Walter Reed Army Medical Center, where he remained on clinical staff for another 11 years. Ajay spent 12 years on the faculty of the Uniformed Services University of the Health Sciences, the US Military’s Medical School. Since leaving the Army as a Lt. Colonel in 2006, Ajay has served in leadership roles at Merck & Co., Inc., Novartis Pharmaceuticals, and Biogen where he directed drug development, biomarkers, and experimental medicine efforts in Alzheimer’s and Parkinson’s disease, ALS, neuropathic pain, multiple sclerosis and other brain and neuromuscular disorders.
Co-Founder and Executive Director
Lou currently serves as the Co-CEO of United Biomedical Inc. and a member of its board of directors. Lou is also a co-founder of Jack Green Group, an investment and advisory firm, with active investments in real estate, energy, healthcare, hospitality, medical devices and biotech. His investments focus on achieving global impact in critically important areas through disruptive and innovative new models and approaches. Lou is passionate about better understanding communities and group flow. He loves all things vision and believes in creating environments in which we can reach our potential to be disruptive originals. Lou received his B.A. from University of Pennsylvania and attended Columbia Business School.
Dr. Chang Yi Wang, PhD
Co-Founder and Chief Scientific Officer
Dr. Wang is the founder of United Biomedical, Inc. and has served as the Chairperson of the Board of Directors since 1998, and as Chief Scientific Officer since December 1985. Dr. Wang is also Chairperson and Chief Executive Officer of UBI-Asia. The UBITh:registered: platform technologies in both designer peptide based immunological applications and in protein and antibody drug development were developed under her direction. From 1981 to 1985, Dr. Wang was a principal investigator and head of the Laboratory of Molecular Immunology at the Memorial Sloan-Kettering Cancer Center in New York and a faculty member of the Department of Immunology, Sloan-Kettering Division, Cornell University Medical School. Dr. Wang received her B.S. degree in Chemistry from National Taiwan University and her Ph.D. degree in Immunology and Biochemistry from The Rockefeller University, New York. She is the principal inventor of over 80 of UBI’s issued patents and patent applications and has published more than 120 peer reviewed scientific papers. In 2007 Dr. Wang received the Inventor of the Year Award from the New York Intellectual Property Law Assocaition (NYPLA).
VP of Clinical Development
PJ joined UNS in 2016. PJ has had a tremendous amount of experience in clinical development and CRO management. Prior to joining UNS, PJ served as head of North Asia at PPD and was responsible for business management and strategy. This included client, project and overall team management in the region with oversight of around 400 staff members. PJ also worked as head of project management and commercial operation for WuxiPRA, a joint venture CRO between WuXi AppTec and PRA Health Sciences. Before serving leadership roles in the CRO industry, PJ served as portfolio development lead at AstraZeneca and was responsible for the successful delivery of AZ development compounds. PJ received graduate training at Massachusetts Institute of Technology and conducted translational medicine research focused on imaging biomarkers at Martinos Center for Biomedical Imaging in Boston.
VP of Finance
Martin, a Qualified Auditor and Chartered Accountant, joined UNS in 2016 with responsibility for financial & management reporting, budgeting and financial systems. Martin has worked over the last decade in strategic / management roles with various multinationals in the pharmaceutical & technology sectors (Pfizer Australia / Dublin, Oracle, Mylan). He has particular expertise in budgeting / control, commercial business partnering and implementing robust financial systems. He holds a BA in Accounting & HRM, Masters in Management Information Systems from University College Dublin and is a member of the Institute of Chartered Accountants of Ireland.
Dr. Feng Lin, MD
Head of Vaccine Design
Dr. Lin joined United Biomedical Inc., in 2005 as a research scientist and leads the vaccine design group. Prior to joining UBI, Dr. Lin practiced medicine as a chief resident and subsequently as chief physician at Beijing People’s Hospital, Beijing Medical School in 1983 and 1986. He became a faculty member in internal medicine at Beijing Medical School in 1985. In 1989, Dr. Lin was selected as an outstanding physician by the medical school for further training as a clinical fellow in Gastroenterology at Essen Medical School, West Germany. In 1990, Dr. Lin was invited as an exchange scholar to join a research team of Hepatology and Molecular Biology in Mount Sinai School of Medicine, New York, and subsequently, as a research scholar at Department of Medicine, College of Physicians and Surgeons, Columbia University. Dr. Lin has 13 scientific publications in prestigious scientific journals, with 6 being first author. Dr. Lin received his medical degree from Xian Medical School and did his internship at the Department of Infectious Diseases in Second Hospital of Xian Medical School.
Dr. Chung-Ho Hung, PhD
Head of Product Development
Dr. Hung joined UBI in 2003 as the Vice President of Biological Product Development. Dr. Hung’s 20 plus years experience in the biotech industry is well-matched to UBI’s proprietary platform technologies. Dr. Hung’s experience encompasses biological product development, including purification of proteins and nature products, and their characterization for IND and PLA [or BLA] regulatory submissions to the FDA and the USDA, GMP manufacturing of biologicals including sterile injectables for immunoglobulin infusion, vaccine products, and blood screening diagnostics. Dr. Hung was previously Co-founder and Vice President of Research and Development of SumMax Corp. in Taiwan and the co-founder and vice president of research and development of Apollo Biomedicals Corp., Dr. Hung was Director of Protein Chemistry at Verigen and Director of Bioprocessing & Protein Chemistry and Senior Director of Research and Development. He is author of more than 27 publications and holds 6 patents. Dr. Hung received his BS degree in plant pathology from National Chung-Hsing University, Taiwan, his MS. in Veterinary Microbiology from Oklahoma State University, his Ph.D. in Biochemistry from the University of Kansas Medical Center.